Trial Profile
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARIEL3
- Sponsors Clovis Oncology [CEASED]
- 30 May 2023 Results published in the Gynecologic Oncology
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.